Adherent cells from placenta and use of same in disease treatment
Methods for treating conditions by administration of placenta derived adherent stromal cells to a subject in thereof are provided. Such conditions include skeletal muscle defects, neuropathic pain, and myocardial infarction. Also provided are methods wherein the adherent stromal cells administered are cultured under 2 dimensional or 3 dimensional growth conditions. Also provided are methods in which the cells administered are at least 70% adherent cells from a maternal or fetal portion of the placenta.
1. A composition comprising:
(a) a population of adherent cells isolated from a placenta, cultured under three-dimensional culturing conditions promoting cell expansion, and harvested from said three-dimensional culturing conditions, wherein the population comprises at least 70% adherent cells from a maternal portion of the placenta, wherein the maternal portion of the placenta is either or both of decidua basalis or decidua parietalis, and wherein the adherent cells do not differentiate into osteogenic or adipogenic lineages when subjected to the same differentiation-inducing conditions as cells derived from bone marrow that differentiate into said lineages; and
(b) an artificial freezing mixture in an amount effective for cryopreservation and subsequent thawing of viable adherent cells.
2. The composition of claim 1 , wherein not more than 3.5% of the population of adherent cells express CD200.
3. The composition of claim 1 , wherein said adherent cells express one or more of CD73, CD90, CD29, CD105 or D7-fib.
4. The composition of claim 1 , wherein said adherent cells do not express CD3, CD4, CD45, CD80, HLA-DR, CD11b, CD19, CD34, CD31, CD200, KDR, or CD79.
5. The composition of claim 1 , wherein said adherent cells comprise a cell diameter which is smaller than that of adherent cells derived from a fetal portion of placenta.
6. The composition of claim 1 , wherein said adherent cells comprise a cell proliferation capacity which is higher than that of adherent cells derived from a fetal portion of placenta.
7. The composition of claim 1 , wherein the freezing mixture comprises dimethyl sulfoxide (DMSO).
8. The composition of claim 1 , wherein the composition is contained in a cryopreservation vial.
9. The composition of claim 1 , wherein the composition is frozen.
10. The composition of claim 9 , wherein the composition is frozen in liquid nitrogen.
11. A method of treating a medical condition in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a population of cells obtained from the composition of claim 1 , thereby treating the subject, wherein the condition is selected from the group consisting of ischemia, peripheral arterial disease (PAD), critical limb ischemia (CLI), lower extremity ischemia, stroke, ischemic vascular disease, vascular disease of the kidney, ischemic heart disease, myocardial ischemia, coronary artery disease (CAD), atherosclerotic cardiovascular disease, left main coronary artery disease, arterial occlusive disease, peripheral ischemia, peripheral vascular disease, arteriosclerosis, retinopathy, retinal repair, remodeling disorder, von Hippel-Lindau syndrome, hereditary hemorrhagic telangiectasia ischemic vascular disease, Buerger's disease, ischemic renal disease, ischemic placenta, reproduction associated disorders, graft-versus-host disease, solid organ transplantation, hematopoietic stem cell transplantation, diabetes, connective tissue damage, cancer, pre-cancer, bone cancer, osteosarcoma, bone metastases, bone fracture, burn wound, articular cartilage defect, deep wound, delayed wound-healing, delayed ulcer healing, subchondral-bone cyst, osteoporosis, osteoarthritis, degenerated bone, cartilage damage, articular cartilage defect, injured tendons, autoimmune diseases, metabolic disorders, psoriasis, neuropathic pain, peripheral nerve injury, neurodegenerative disease, support of kidney transplantation and inflammatory diseases.
12. The method of claim 11 , wherein the condition is heart failure, myocardial infarction, neuropathic pain, skeletal muscle defect, stroke, or ischemic heart disease.
13. The method of claim 12 , wherein the condition is skeletal muscle defect.
14. The method of claim 12 , wherein the condition is myocardial infarction.
15. The method of claim 12 , wherein the condition is neuropathic pain.
16. The method of claim 15 , wherein the neuropathic pain is associated with inflammatory pain, diabetic polyneuropathy, human immunodeficiency virus (HIV) sensory neuropathy, post-stroke syndromes, ischemia, or multiple sclerosis.
17. The method of any one of claims 13 , 15 , or 14 , wherein said adherent cells express one or more of CD73, CD90, CD29, CD105 or D7-fib.
18. The method of any one of claims 13 , 15 , or 14 , wherein said adherent cells do not express CD3, CD4, CD45, CD80, HLA-DR, CD11b, CD14, CD19, CD34, CD31, CD200, CD271, KDR, or CD79.
19. The method of any one of claims 13 , 15 , or 14 , wherein said adherent cells express one or more of beta-Endorphin, dynorphin A, leuenkephalin, or met-enkephalin.
20. The method of any one of claims 13 , 15 , or 14 , wherein said adherent cells comprise at least 70% adherent cells from a maternal portion of the placenta.
21. The method of claim 20 , wherein not more than 3.5% of the adherent cells express CD200.